#ECTRIMS2021 – Trial Analyses Support Evobrutinib for Relapsing MS

#ECTRIMS2021 – Trial Analyses Support Evobrutinib for Relapsing MS

308278

#ECTRIMS2021 – Trial Analyses Support Evobrutinib for Relapsing MS

Treatment with evobrutinib, an experimental therapy for relapsing forms of multiple sclerosis (MS), reduced the size of inflammation-associated brain lesions in a Phase 2 clinical trial, data show. The oral medication was also found to be generally safe and well-tolerated, according to an analysis of trial data in MS and other autoimmune diseases. Findings will be shared in a series of presentations at the 37th Congress of the European Committee for Treatment and Research in…

You must be logged in to read/download the full post.